Influences of HLA Class I Polymorphisms on Immune Responses
Influences of HLA Class I Polymorphisms on Immune Responses
批准号:
10326865
负责人:
MALINI RAGHAVAN
金额:
$46.52万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-15 至 2024-01-31
关键词:
AddressAffectAllelesAntigen ReceptorsAntigen-Presenting CellsAntigensAutoimmune DiseasesAutoimmunityB-LymphocytesBehaviorBindingCD8 receptorCD8-Positive T-LymphocytesCD8B1 geneCell AdhesionCell physiologyCell surfaceCellsCharacteristicsCommunicable DiseasesCompetenceComplexCross PresentationCytoplasmDiseaseDrug HypersensitivityEBV specific T-cellsElementsEndoplasmic ReticulumEnvironmentEpstein-Barr Virus InfectionsGenesGenetic PolymorphismHLA AntigensHistocompatibility Antigens Class IHumanHuman CharacteristicsHuman Herpesvirus 4ImmuneImmune TargetingImmune responseImmune systemImmunityIndividualInflammatoryKnowledgeLeadLigationLightLinkLymphocyteMalignant NeoplasmsMediatingMembraneModelingMolecular ChaperonesMolecular ConformationMutationNK Cell ActivationNatural Killer CellsNeoplasmsOutcomePathway interactionsPatternPeptidesPersonsPhenotypePlayPopulationProcessPropertyProteinsQuality ControlResistanceSourceSpecificityStructureSubgroupT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTextbooksVaccine DesignVaccinesVariantViralViral ProteinsVirus Diseasesantigen processingantigenic peptide transporterarmbasecancer immunotherapygraspimmunological interventionimprovedinhibitormonocytemultimodalitynovelpathogenpeptide Iprecision medicinepreferenceprotein foldingtapasintrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Human leukocyte antigen (HLA) class I molecules have profound influences on infectious disease and cancer
outcomes, via effects on immunity mediated by CD8+ T cells and natural killer (NK) cells. Three sets of genes,
HLA-A, HLA-B and HLA-C encode HLA class I proteins. These genes are among the most polymorphic of
human genes, with thousands of alleles found in humans. Each allotype presents a unique set of peptides at
the cell surface, and individual peptides in complex with HLA class I molecules confer exquisite specificity for
recognition by T cell receptors (TCR) of CD8+ T cells. In the canonical textbook-defined HLA class I assembly
pathway, peptides that bind to HLA class I molecules are typically derived from the cytoplasm of cells, and
transported into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP).
In the ER, peptides assemble with HLA class I molecules in a process that is guided by specific assembly
factors such as tapasin and generic ER chaperones. Peptide-loaded versions of HLA class I molecules exit the
ER, whereas ER quality control is thought to retrieve peptide-deficient HLA class I for degradation, due to their
relative instability. A number of our recent findings indicate that the canonical assembly pathway does not fully
account for cell surface expression patterns of HLA-B allotypes in all cells, and additionally that peptide-
deficient (empty) HLA-B do exist at the cell surface under some conditions, and are functional in the immune
response. Based on these findings, it is our central hypothesis that HLA-B allotypes are functionally separable
based on the stabilities of their empty forms and their peptide-binding preferences, and that these
characteristics determine their competence for non-canonical assembly pathways and related functions. To
test this hypothesis, we examine the model that HLA-B allotypes vary both in their constitutive cell surface
expression levels and in cross-presentation efficiencies in antigen presenting cells (APC), based on
competence for non-canonical assembly. We also examine the model that HLA-B allotypes vary in their
abilities to induce effective CD8+ T cell immunity against Epstein Barr Virus (EBV) infections due to varying
competencies for assembly in a TAP-deficient environment. Finally, the models of differential induction and
novel functions for empty HLA-B in CD8+ T cell and NK cell functions are examined. Together, these studies
address the central idea that the extreme polymorphisms of the HLA-B locus, which are evolutionarily-selected
mutations within a confined region of the HLA class I structure, generate a hierarchy of protein folding and
assembly phenotypes that are exploited by distinct arms of the immune response to maintain multi-
compartmental and multimodal surveillance. These studies are expected to guide our progress in precision
medicine by identifying best candidate HLA-B for specific vaccine targets, and provide new targets for
combatting HLA-B-driven autoimmunity and drug hypersensitivity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HLA class I peptidome diversities and CD8+ T cell responses to COVID-19 vaccines
-
批准号:10632096
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2022
-
负责人:MALINI RAGHAVAN
-
依托单位:
HLA class I peptidome diversities and CD8+ T cell responses to COVID-19 vaccines
-
批准号:10523733
-
项目类别:
-
资助金额:$18.83万
-
财政年份:2022
-
负责人:MALINI RAGHAVAN
-
依托单位:
Peptide Repertoires of HLA class I molecules
-
批准号:9316821
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2017
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin-mediated protein folding in health and disease
-
批准号:10599361
-
项目类别:
-
资助金额:$45.13万
-
财政年份:2016
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin-mediated protein folding in health and disease
-
批准号:10362228
-
项目类别:
-
资助金额:$45.81万
-
财政年份:2016
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin-mediated protein folding in health and disease
-
批准号:9095546
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2016
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin-mediated protein folding in health and disease
-
批准号:9238654
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2016
-
负责人:MALINI RAGHAVAN
-
依托单位:
Interactions and mechanisms of function of the TAP complex
-
批准号:7881378
-
项目类别:
-
资助金额:$2.29万
-
财政年份:2009
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7881344
-
项目类别:
-
资助金额:$2.29万
-
财政年份:2009
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7924278
-
项目类别:
-
资助金额:$38.91万
-
财政年份:2009
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7213582
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2007
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7775065
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2007
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7586139
-
项目类别:
-
资助金额:$35.11万
-
财政年份:2007
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7575527
-
项目类别:
-
资助金额:$3.86万
-
财政年份:2007
-
负责人:MALINI RAGHAVAN
-
依托单位:
Calreticulin's functions in the adaptive immune response
-
批准号:7384495
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2007
-
负责人:MALINI RAGHAVAN
-
依托单位:
INTERACTIONS & MECHANISMS OF FUNCTION OF THE TAP COMPLEX
-
批准号:6341725
-
项目类别:
-
资助金额:$17.24万
-
财政年份:1999
-
负责人:MALINI RAGHAVAN
-
依托单位:
Interactions & mechanisms of function of the TAP complex
-
批准号:6859387
-
项目类别:
-
资助金额:$30.38万
-
财政年份:1999
-
负责人:MALINI RAGHAVAN
-
依托单位:
Influences of HLA Class I Polymorphisms on immune responses
-
批准号:8878984
-
项目类别:
-
资助金额:$43.14万
-
财政年份:1999
-
负责人:MALINI RAGHAVAN
-
依托单位:
Interactions and mechanisms of function of the TAP complex
-
批准号:8006401
-
项目类别:
-
资助金额:$37.85万
-
财政年份:1999
-
负责人:MALINI RAGHAVAN
-
依托单位:
Interactions & mechanisms of function of the TAP complex
-
批准号:7032349
-
项目类别:
-
资助金额:$29.51万
-
财政年份:1999
-
负责人:MALINI RAGHAVAN
-
依托单位:
海外基金